Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protected Class Lobbying Begin

This article was originally published in RPM Report

Executive Summary

Bayer is CMS to add multiple sclerosis to the list of drug classes protected from formulary restrictions under the Medicare Part D prescription drug program. The first request to broaden the list of protected classes won't be the last.

You may also be interested in...

Class Warfare: CMS Proposes Sweeping Changes to Part D; “Protected Class” Cuts Just the Start

The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.

Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors

Democrats failed in their first attempt to impose price controls in Medicare Part D. But, led by California Rep. Waxman, they may have found a new approach that seems less threatening than price negotiations-rebates for products used by dual eligible patients. And the drugs most likely to be affected are in Part D's six protected classes.

Too Many Middlemen? Long-Term Care Pharmacies are Losing Fight for Control of Part D Formularies

Omnicare's lawsuit against UnitedHealth Group is part of a battle for survival by long-term care pharmacy providers. The stakes for manufacturers are high: who can really deliver market share under Part D?

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts